FOGHORN THERAPEUTICS INC (FHTX) competitors & alternatives
Health Care · NASDAQ
FOGHORN THERAPEUTICS INC (FHTX)'s top competitors and alternatives — its most similar public companies — include KARYOPHARM THERAPEUTICS INC (KPTI), KURA ONCOLOGY INC (KURA), CYTOMX THERAPEUTICS INC (CTMX), NURIX THERAPEUTICS INC (NRIX), PERSPECTIVE THERAPEUTICS INC (CATX), MONTE ROSA THERAPEUTICS INC (GLUE), TANGO THERAPEUTICS INC (TNGX), PRECIGEN INC (PGEN), ASTRAZENECA PLC (AZN), ORIC PHARMACEUTICALS INC (ORIC), DYNE THERAPEUTICS INC (DYN) and PTC THERAPEUTICS INC (PTCT). These are FOGHORN THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top FHTX competitors & alternatives
-
KARYOPHARM THERAPEUTICS INCKPTIHealth Care
Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in…
$7.18 (as of 2026-07-22) · market cap $178M
-
KURA ONCOLOGY INCKURAHealth Care
Clinical-stage oncology company commercializing KOMZIFTI for cancer and advancing a pipeline of targeted therapeutics through strategic partnerships.
$10.54 (as of 2026-07-22) · market cap $944M
-
CYTOMX THERAPEUTICS INCCTMXHealth Care
CytomX is developing conditionally activated cancer therapies using its PROBODY platform to enable selective tumor targeting with reduced systemic toxicity,…
$3.33 (as of 2026-07-22) · market cap $724M
-
NURIX THERAPEUTICS INCNRIXHealth Care
Clinical-stage biotech pioneering AI-powered targeted protein degradation medicines for cancer and autoimmune diseases, with Phase 2 lead candidate…
$23.60 (as of 2026-07-22) · market cap $2.4B
-
PERSPECTIVE THERAPEUTICS INCCATXHealth Care
Perspective Therapeutics is a clinical-stage oncology company pioneering targeted alpha therapy (TAT) to treat cancer through a proprietary radiopharmaceutical…
$2.97 (as of 2026-07-22) · market cap $337M
-
MONTE ROSA THERAPEUTICS INCGLUEHealth Care
Monte Rosa Therapeutics develops molecular glue degraders—a novel class of protein degradation drugs targeting historically undruggable proteins through its…
$23.79 (as of 2026-07-22) · market cap $2.0B
-
TANGO THERAPEUTICS INCTNGXHealth Care
A precision oncology company utilizing a proprietary functional genomics platform to discover and develop targeted, synthetic-lethal cancer therapies.
$28.10 (as of 2026-07-22) · market cap $4.6B
-
PRECIGEN INCPGENHealth Care
Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and…
$5.32 (as of 2026-07-22) · market cap $1.9B
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
ORIC PHARMACEUTICALS INCORICHealth Care
ORIC Pharmaceuticals is a clinical-stage oncology company developing targeted therapies for hard-to-treat cancers through precision medicine approaches.
$10.75 (as of 2026-07-22) · market cap $1.1B
-
DYNE THERAPEUTICS INCDYNHealth Care
Dyne Therapeutics is a clinical-stage biotechnology company leveraging its proprietary FORCE platform to develop targeted therapies for serious,…
$23.21 (as of 2026-07-22) · market cap $3.8B
-
PTC THERAPEUTICS INCPTCTHealth Care
PTC Therapeutics develops precision medicines and gene therapies targeting rare genetic disorders and serious diseases, generating revenue from approved…
$78.40 (as of 2026-07-22) · market cap $6.5B
Not quite? Describe exactly what you want →
Peers are FOGHORN THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: FOGHORN THERAPEUTICS INC (FHTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.